•  

BlueDot

BlueDot profiled in Toronto Star for anticipating Zika virus spread

BlueDot, a Canadian company that helps decision-makers prepare for and response to infectious disease outbreaks, was profiled in the Toronto Star for their work in tracking the Zika virus. The company, founded by Dr. Kamran Khan, was spun-off from St. Michael's Hospital in partnership with MaRS Innovation. The company raised a Series A with Horzions Ventures in 2015. Here's an excerpt from Kate Allen's article: Wayne Gretzky may be an unlikely inspiration for an infectious disease researcher. Yet here Dr. Kamran Khan is, on ... Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ... Read more

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases. Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded ... Read more

MaRS Innovation’s 2013 Top 10 List

2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio. 1. MaRS Innovation secures a $15 million CECR funding extension In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada. This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ... Read more

BioDiaspora predicts Hajj and Umrah as two key possible spread points for MERS coronavirus

BioDiaspora, a start-up company based on the research of company founder, Dr. Kamran Khan of St. Michael's Hospital, has identified two mass gatherings in the Islamic world as key possible spread points for the life-threatening MERS coronavirus, which emerged in the Middle East in early 2012. BioDiaspora's disease-tracking platform, which correlates uses global air traffic patterns to predict the international spread of infectious disease (as described in the original media release from St. Michael's Hospital): The first is umrah, a pilgrimage that can ... Read more

BioDiaspora among technologies redefining digital disease mapping

Dr. Kamran Khan, founder of BioDiapsora, was cited in a New York Times' Bits article on the Big Data solutions evolving to track the global spread of disease: "In New Tools to Combat Epidemics, the Key is Context." Amy O'Leary's article appeared as part of a special blog/supplement on June 19, 2013 (Big Data 2013). Here's an excerpt (links and emphasis ours): One of the doctors in the field who can benefit from these types of insights is Dr. Kamran Khan, an infectious disease ... Read more

Is screening air travellers effective in containing a pandemic?

Toronto Star covers Khan's new WHO paper on H1N1 outbreak Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael’s Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China and the new coronavirus in the Middle East and Europe. Global News National also covered this story on April 11, 2013. Watch Beatrice Politi and Carmen Chai's report, "Canadian scientists pioneer new formula in airport disease screening," on the Global website. The ... Read more

BioDiaspora Founder: Travellers unlikely to bring H7N9 bird flu to Canada

Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael's Hospital, is among the experts studying the emergence of the H7N9 bird flu outbreak in China. Jennifer Yang interviewed Khan in today's Toronto Star about the likelihood of the disease being easily transmitted from human to human or arriving in Canada, as SARS did in 2003. Here's an excerpt: “This isn’t necessarily an event that poses a significant risk to Canada, at least based on all the current ... Read more

Dr. Kamran Khan, founder of BioDiaspora, among experts studying emergence of coronavirus

Health risk to Canadians is currently low Dr. Kamran Khan, founder of BioDiaspora and an infectious disease physician and scientist at St. Michael's Hospital, is among the experts studying the emergence of the coronavirus. Carolyn Brown interviewed Khan for a recent CMAJ article on the viral outbreak, "New coronavirus with 'pandemic potential' sparks global surveillance efforts." (more…) Read more

BioDiaspora Founder Kamran Khan interviewed in Maclean’s Magazine

India's Kumbh Mela, an annual mass Hindu pilgrimage of faith, is unlikely to create a disease outbreak that spreads beyond the country's borders, Dr. Kamran Khan, founder of BioDiaspora, tells Maclean's Magazine's Hannah Hoag in "As millions gather for Kumbh Mela, doctors are watching" (February 11, 2013). Here's an excerpt (emphasis ours): Unlike the hajj or the Olympics, the Kumbh Mela is primarily a domestic event. While flights into Saudi Arabia spike to five times normal during the hajj, “with the Kumbh Mela, ... Read more